AAN 2023 | Inebilizumab in AQP4+ NMOSD patients with history of immunosuppression treatment: N-MOmentum study

Friedemann Paul, MD, Charité-Universitätsmedizin Berlin, Berlin, Germany, describes the findings from an analysis evaluating long-term outcomes of inebilizumab treatment in AQP4+ NMOSD participants from the N-MOmentum trial (NCT02200770) with a history of immunosuppressant therapy as compared to those without. N-Momentum was a 28-week-randomized Phase II/III trial of inebilizumab vs. placebo, with an optional open-label extension. In the analysis, AQP4+ participants who received inebilizumab were grouped by no history of immunosuppression therapy beyond the treatment of acute NMOSD attacks (naïve) or prior azathioprine (AZA) and/or mycophenolate mofetil (MMF) therapy. Results showed that AQP4+ NMOSD participants treated with prior AZA/MMF therapy demonstrated a similar efficacy and safety profile as participants without prior immunosuppressant therapy. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.